Healthcare / Medical DevicesKOSDAQ
$1331.00
-54.00 (-3.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-25.7B · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$101.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.3%
↓Gross Margin
36.1%
↓Debt/Equity
1.15
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
—
FCF margin
-23.1%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $116.30B · net income $-24.03B · FCF $-26.90B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $116.30B | $116.30B | $97.56B | $92.44B | $89.48B |
| Net Income | $-24.03B | $-24.03B | $-19.29B | $-2.25B | $5.97B |
| EBITDA | $-6.64B | $-6.64B | $-4.39B | $9.10B | $13.09B |
| EPS | -321.00 | -321.00 | -262.00 | -34.00 | 96.00 |
| Gross Margin | 36.1% | 36.1% | 40.5% | 45.8% | 45.0% |
| Operating Margin | -11.9% | -11.9% | -12.4% | -0.2% | 5.5% |
| Net Margin | -20.7% | -20.7% | -19.8% | -2.4% | 6.7% |
| Balance Sheet | |||||
| Debt/Equity | 1.15 | 1.15 | 1.07 | 0.68 | 0.65 |
| Current Ratio | 1.70 | 1.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26.90B | $-26.90B | $-25.68B | $-17.89B | $-2.76B |
| Returns | |||||
| ROE | -31.3% | -31.3% | -26.5% | -2.7% | 9.9% |
| Valuation | |||||
| P/E | — | — | — | — | 14.58 |
| EV/EBITDA | — | — | — | 38.49 | 8.59 |
| P/B | 1.30 | 1.30 | 2.41 | 3.60 | 1.44 |
| Growth & Yield | |||||
| Revenue Growth | 19.2% | 19.2% | 5.5% | 3.3% | — |
| EPS Growth | -22.5% | -22.5% | -670.6% | -135.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-262.00 → -321.00
Residual
-27.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.